Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Essential Thrombocythemia
MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis
A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Care Setting Influences Likelihood Extreme Thrombocytosis Is Due to Blood Cancer
Although extreme thrombocytosis occurs rarely, researchers were able to identify its underlying cause and potential prognosis for patients who develop the condition.
Quantifying Driver Alterations in BCR-ABL1-Negative Myeloproliferative Neoplasms
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
Ruxolitinib is Associated With Improved Renal Function in Patients With Primary Myelofibrosis
A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.
Age at Diagnosis of Myeloproliferative Neoplasm Affects Pattern of Thrombotic Events but Not Mortality Risk
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
Myeloproliferative Neoplasm Symptom Burden High for UK Patients, Physicians
An analysis of responses to the 2017 Landmark Survey revealed that disease-burden symptoms of MPN is challenging for both patients with the disease and their physicians.
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
Next post in Myeloproliferative Neoplasms
